Kymera Therapeutics (NASDAQ:KYMR) Sets New 52-Week High at $50.69

Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $50.69 and last traded at $50.11, with a volume of 214083 shares changing hands. The stock had previously closed at $46.44.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on KYMR. Morgan Stanley raised their price target on shares of Kymera Therapeutics from $34.00 to $45.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 14th. Wells Fargo & Company boosted their target price on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a research report on Monday, August 12th. HC Wainwright reaffirmed a “buy” rating and set a $46.00 price target on shares of Kymera Therapeutics in a research report on Monday, June 17th. Leerink Partnrs upgraded Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Finally, B. Riley upped their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research note on Tuesday, July 9th. Four investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $48.67.

Kymera Therapeutics Price Performance

The company has a market capitalization of $3.06 billion, a P/E ratio of -19.84 and a beta of 2.22. The company has a fifty day moving average price of $45.28 and a 200 day moving average price of $39.09.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.58) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.10. The firm had revenue of $25.60 million during the quarter, compared to the consensus estimate of $12.55 million. Kymera Therapeutics had a negative return on equity of 28.88% and a negative net margin of 178.27%. The firm’s revenue was up 55.2% on a year-over-year basis. During the same period in the prior year, the business earned ($0.67) EPS. On average, equities research analysts predict that Kymera Therapeutics, Inc. will post -2.87 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bruce Booth sold 453,960 shares of the business’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $38.21, for a total transaction of $17,345,811.60. Following the completion of the transaction, the director now directly owns 723,246 shares of the company’s stock, valued at approximately $27,635,229.66. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, Director Bruce Booth sold 453,960 shares of the firm’s stock in a transaction that occurred on Tuesday, July 9th. The stock was sold at an average price of $38.21, for a total value of $17,345,811.60. Following the sale, the director now directly owns 723,246 shares in the company, valued at approximately $27,635,229.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jared Gollob sold 23,145 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $45.81, for a total value of $1,060,272.45. Following the transaction, the insider now owns 95,470 shares of the company’s stock, valued at approximately $4,373,480.70. The disclosure for this sale can be found here. Insiders have sold a total of 495,605 shares of company stock valued at $19,303,364 in the last quarter. Company insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in shares of Kymera Therapeutics in the 2nd quarter worth approximately $1,910,000. Algert Global LLC raised its holdings in Kymera Therapeutics by 16.5% during the second quarter. Algert Global LLC now owns 32,706 shares of the company’s stock worth $976,000 after purchasing an additional 4,622 shares in the last quarter. Driehaus Capital Management LLC bought a new stake in Kymera Therapeutics during the second quarter worth approximately $6,669,000. Susquehanna Fundamental Investments LLC lifted its position in Kymera Therapeutics by 7.4% in the second quarter. Susquehanna Fundamental Investments LLC now owns 76,818 shares of the company’s stock worth $2,293,000 after purchasing an additional 5,325 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its stake in Kymera Therapeutics by 13.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 130,077 shares of the company’s stock valued at $3,883,000 after purchasing an additional 15,320 shares in the last quarter.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.